✅ Model Answer:
• Diagnosis: Hemorrhagic cystitis (cyclophosphamide-induced – acrolein metabolite).
• Evidence: Cyclophosphamide use (leukemia treatment), gross hematuria, dysuria, suprapubic pain, sterile urine culture.
• Next step: Hydration (IV fluids), bladder irrigation, analgesia. Prevention: mesna and hydration before and after cyclophosphamide. Long-term risk: bladder cancer.

✅ Model Answer:
• Cyclophosphamide: An alkylating agent used in chemotherapy (leukemia, lymphoma, solid tumors).
• Metabolism: Cyclophosphamide is metabolized in the liver to acrolein (toxic metabolite) and phosphoramide mustard (active antitumor agent).
• Acrolein: Excreted in the urine and causes direct toxic injury to the bladder urothelium → mucosal inflammation, ulceration, hemorrhage.
• Risk factors: High cumulative dose, dehydration, prior radiation, concurrent ifosfamide.
• Onset: Can occur during or after treatment (delayed up to months to years).

✅ Model Answer:
• Classic features:
- Gross hematuria: Blood in urine (varying severity).
- Dysuria: Painful urination.
- Suprapubic pain: Lower abdominal pain.
- Frequency, urgency.
- Sterile urine: Negative urine culture (no infection).
• Other features:
- Clots: May cause urinary retention.
- Anemia: If significant blood loss.
- Secondary infection: If mucosal barrier is breached.
- Late complication: Bladder fibrosis, contracture, or malignancy (transitional cell carcinoma) – long-term risk.

✅ Model Answer:
• Urinalysis: Gross or microscopic hematuria, pyuria (WBCs), no bacteria (sterile).
• Urine culture: Negative (rules out infection).
• Serum creatinine: To assess renal function (usually normal).
• CBC: Anemia (if blood loss).
• Imaging:
- Renal/bladder ultrasound: May show bladder wall thickening, clots, or hydronephrosis (if obstruction).
- Cystoscopy: For severe cases – shows hemorrhagic mucosa, ulceration.
• Biopsy: Not routinely needed; may show inflammation, necrosis, or atypical cells (if malignancy suspected).

✅ Model Answer:
• Supportive care:
- Hydration: IV fluids to maintain urine output (>2 mL/kg/hour) and dilute acrolein.
- Bladder irrigation: Continuous or intermittent irrigation with normal saline (to remove clots).
- Analgesia: Pain control (acetaminophen, opioids if needed).
- Anticholinergics: Oxybutynin for frequency/urgency.
• Specific therapy:
- Mesna: Administered with cyclophosphamide to neutralize acrolein in the bladder (preventive). If hemorrhagic cystitis occurs, mesna may still be given.
- Hemostatic agents: Aminocaproic acid (EACA) or tranexamic acid (if bleeding is severe).
- Blood transfusion: If significant anemia.
- Cystoscopy: For clot evacuation or cauterization (if severe).
• Long-term: Monitor for bladder fibrosis and malignancy.

✅ Model Answer:
• Acute:
- Urinary retention: Due to clots obstructing the urethra.
- Anemia: From blood loss (may require transfusion).
- Secondary infection: Urinary tract infection (if mucosal integrity is compromised).
- Sepsis.
• Chronic (late-onset):
- Bladder fibrosis: Scarring → reduced bladder capacity, contracture.
- Vesicoureteral reflux: Due to fibrosis of the ureteric orifice.
- Hydronephrosis.
- Chronic kidney disease.
- Transitional cell carcinoma: Increased risk of bladder cancer (10-15 years after cyclophosphamide).
• Other: Poor quality of life due to chronic urinary symptoms.

✅ Model Answer:
• Prognosis:
- Good with prompt hydration and bladder irrigation.
- Mild cases: Resolve with supportive care.
- Severe cases: May require cystoscopy, hyperbaric oxygen, or surgical intervention.
- Late complications: Bladder fibrosis and malignancy (rare in children).
- Recurrence: Risk with subsequent cyclophosphamide doses (if not prevented with mesna).
• Long-term follow-up:
- Monitor for recurrence: Especially if cyclophosphamide is continued.
- Monitor for bladder cancer: Annual urinalysis after 10 years of treatment.
- Cystoscopy: If persistent hematuria or symptoms.
- Education: Encourage hydration during chemotherapy; use mesna as prevention.

✅ Model Answer:
• Mesna (sodium 2-mercaptoethanesulfonate): A sulfhydryl compound that inactivates acrolein in the bladder.
• Mechanism:
- Mesna is excreted in the urine and reacts with acrolein to form a stable, non-toxic thioether compound.
- Prevents acrolein-induced bladder damage.
• Administration:
- Dose: 60% of the cyclophosphamide dose (e.g., 15-20 mg/kg) given IV before and after cyclophosphamide.
- Timing: Given with cyclophosphamide and repeated at 4, 8, 12 hours (depending on protocol).
• Indications: All patients receiving cyclophosphamide or ifosfamide (especially high-dose).
• Side effects: Nausea, vomiting, headache, rash (rare).
• Effectiveness: Reduces the incidence of hemorrhagic cystitis from 30-50% to <5%.